- Home
- ATNI vs NBTX Comparison
ATNI vs NBTX Comparison
Compare ATNI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- NBTX
- Stock Information
- Founded
- ATNI 1987
- NBTX 2003
- Country
- ATNI United States
- NBTX France
- Employees
- ATNI N/A
- NBTX N/A
- Industry
- ATNI Telecommunications Equipment
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- NBTX Health Care
- Exchange
- ATNI Nasdaq
- NBTX Nasdaq
- Market Cap
- ATNI 240.6M
- NBTX 201.9M
- IPO Year
- ATNI 1991
- NBTX 2020
- Fundamental
- Price
- ATNI $15.32
- NBTX $3.03
- Analyst Decision
- ATNI Strong Buy
- NBTX Strong Buy
- Analyst Count
- ATNI 2
- NBTX 1
- Target Price
- ATNI $31.00
- NBTX $12.00
- AVG Volume (30 Days)
- ATNI 102.7K
- NBTX 42.0K
- Earning Date
- ATNI 02-19-2025
- NBTX 09-18-2024
- Dividend Yield
- ATNI 6.27%
- NBTX N/A
- EPS Growth
- ATNI N/A
- NBTX N/A
- EPS
- ATNI N/A
- NBTX N/A
- Revenue
- ATNI $747,493,000.00
- NBTX $45,220,186.00
- Revenue This Year
- ATNI N/A
- NBTX N/A
- Revenue Next Year
- ATNI $1.20
- NBTX N/A
- P/E Ratio
- ATNI N/A
- NBTX N/A
- Revenue Growth
- ATNI N/A
- NBTX 526.17
- 52 Week Low
- ATNI $14.85
- NBTX $2.76
- 52 Week High
- ATNI $38.96
- NBTX $8.43
- Technical
- Relative Strength Index (RSI)
- ATNI 32.34
- NBTX 46.58
- Support Level
- ATNI $14.90
- NBTX $2.85
- Resistance Level
- ATNI $16.85
- NBTX $3.07
- Average True Range (ATR)
- ATNI 0.77
- NBTX 0.16
- MACD
- ATNI 0.07
- NBTX 0.04
- Stochastic Oscillator
- ATNI 20.26
- NBTX 45.65
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise US Telecom and International Telecom. The company earns revenue from its telecommunication services.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.